Table 3.
Multivariable Adjusted1 Risk of Incident Symptoms Prior to stopping2 by Prevalence of Symptoms at Baseline3: WHI CEE cohort (n=3496)4
| Symptom Prevalence At Baseline | CEE %5 (N6) | Placebo % (N) | RR (95% CI)7 | P8 | P-int9 |
|---|---|---|---|---|---|
| Hot Flashes | |||||
| Not present | 0.9 (1460) | 2.3 (1557) | 0.42 (0.22, 0.81) | 0.01 | 0.36 |
| Present | 10.1 (218) | 15.9 (176) | 0.62 (0.36, 1.06) | ||
| Night Sweats | |||||
| Not Present | 3.4 (1450) | 4.3 (1547) | 0.83 (0.57, 1.21) | 0.04 | 0.23 |
| Present | 15.7 (223) | 27.3 (172) | 0.59 (0.40, 0.88) | ||
| Breast Tenderness | |||||
| Not Present | 4.3 (1642) | 2.3 (1706) | 1.81 (1.20, 2.75) | 0.002 | 0.59 |
| Present | 40.0 (35) | 23.3 (30) | 1.42 (0.65, 3.06) | ||
| Vaginal Dryness | |||||
| Not Present | 5.3 (1508) | 5.4 (1586) | 0.99 (0.72, 1.35) | 0.52 | 0.26 |
| Present | 25.6 (164) | 36.1 (147) | 0.76 (0.54, 1.07) | ||
| Joint Pain | |||||
| Not Present | 20.4 (1213) | 19.5 (1248) | 1.08 (0.91, 1.28) | 0.15 | 0.98 |
| Present | 58.0 (462) | 52.9 (484) | 1.08 (0.96, 1.22) | ||
| Mood Swings | |||||
| Not Present | 4.7 (1559) | 4.2 (1624) | 1.21 (0.85, 1.73) | 0.59 | 0.19 |
| Present | 28.6 (112) | 30.5 (105) | 0.83 (0.54, 1.27) | ||
1
Adjusted for age at baseline, years since menopause and prior hormone use.
2
Incidence of moderate or severe symptoms prior to stopping study pills.
3
Prevalence of moderate or severe symptoms at Baseline.
4
Women that were eligible (were not deceased, stopped or lost to follow-up and were still taking study pills) and completed all surveys
5
Proportion of N reporting symptoms prior to stopping study pills.
6
N = total number of participants; denominator of (5).
7
Multivariable adjusted relative risk (95% confidence interval) of symptoms at prior to stopping of CEE compared to placebo.
8
Test of main effect.
9
Test of interaction.